In the beginning of this year, I wrote two articles concerning torcetrapib, the $800 million failure of Pfizer to develop a new type of cholesterol medication. This novel medication called a CETP (cholesterol ester transfer protein) inhibitor is able to markedly raise HDL, but unfortunately was found to increase the risk of death. The... Read more
Now that National Cholesterol Education Month has ended, I thought this would be a good time to highlight some of the recent accomplishments in cholesterol treatment during this past year. But it's only fair to also highlight some of our recent failures as well. Looking at both our successes and failures helps us to gain a perspective on... Read more
It's quite commonly known that high total cholesterol and LDL levels are directly related to an increased risk of heart disease and that the relationship is graded and continuous. This risk even applies to people under the age of 40. Low HDL and high triglycerides also contribute to this risk but apparently to a lesser extent, especially... Read more
Now that we are all rested after our long Labor Day weekend, I thought it important to remind you that September has been designated National Cholesterol Education Month. Yes, there really is such a thing. There's a breast cancer awareness month, prostate cancer awareness month, a foot health awareness month, and a medical... Read more
As mentioned in my previous article, non pharmacological treatment for high triglyceride (TG) levels can be quite effective with diet and exercise alone contributing to an almost 33% reduction. However, for some this may not be enough, and for others the effect may be too difficult to maintain over the long run. Medication to lower TG levels... Read more